协同照护模式对印度抑郁合并糖尿病患者抑郁症状及心脏代谢指标的影响:INDEPENDENT随机临床试验
该平行、开放标签、实用性随机临床试验在印度4家社会经济条件不同的诊所纳入404例2型糖尿病合并抑郁的成人患者。干预组接受12个月由非医师照护协调员提供的自我管理支持、决策支持电子健康档案及专科病例审查,对照组接受常规照护。24个月时,干预组达到主要复合结局的比例显著高于对照组(71.6% vs 57.4%)。
要点
- 协同照护可提高抑郁合并糖尿病患者达到抑郁症状与心脏代谢指标复合改善的比例。
- 干预为期12个月,随访至24个月,效果在停止干预后仍可观察到。
- 在16项预设次要结局中,多数未显示统计学显著组间差异。
核心结论
- 在印度抑郁合并糖尿病患者中,与常规照护相比,12个月协同照护干预在24个月时使抑郁症状与心脏代谢指标的复合结局获得统计学显著改善。
研究设计与样本
- 平行、开放标签、实用性随机临床试验,在印度4家社会经济条件不同的诊所开展。
- 纳入标准为2型糖尿病、患者健康问卷-9评分至少10分(范围0-27),且HbA1c至少8%、收缩压至少140 mm Hg或LDL胆固醇至少130 mg/dL。
- 干预组196例接受12个月协同照护并额外随访12个月,对照组208例接受24个月常规照护。
- 共404例患者随机(平均[SD]年龄53[8.6]岁;165例[40.8%]男性),378例(93.5%)完成试验。
主要发现
- 24个月时,干预组达到主要复合结局的比例为71.6%,对照组为57.4%,风险差16.9%(95%CI,8.5%-25.2%)。
- 在16项预设次要结局中,12个月时10项、24个月时13项的组间改善差异无统计学显著性。
- 严重不良事件:干预组与对照组心血管事件或住院分别为4例(2.0%)与7例(3.4%),卒中0例与3例(1.4%),死亡2例(1.0%)与7例(3.4%),严重低血糖8例(4.1%)与0例。
临床怎么用
- 对于资源有限地区抑郁合并糖尿病的成人患者,可考虑采用由非医师照护协调员、决策支持电子健康档案和专科病例审查组成的协同照护模式。
局限性
- 研究结果在其它中低收入卫生保健环境中的可推广性尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Mental health comorbidities are increasing worldwide and worsen outcomes for people with diabetes, especially when care is fragmented. OBJECTIVE: To assess whether collaborative care vs usual care lowers depressive symptoms and improves cardiometabolic indices among adults with diabetes and depression. DESIGN, SETTING, AND PARTICIPANTS: Parallel, open-label, pragmatic randomized clinical trial conducted at 4 socioeconomically diverse clinics in India that recruited patients with type 2 diabetes; a Patient Health Questionnaire-9 score of at least 10 (range, 0-27); and hemoglobin A1c (HbA1c) of at least 8%, systolic blood pressure (SBP) of at least 140 mm Hg, or low-density lipoprotein (LDL) cholesterol of at least 130 mg/dL. The first patient was enrolled on March 9, 2015, and the last was enrolled on May 31, 2016; the final follow-up visit was July 14, 2018. INTERVENTIONS: Patients randomized to the intervention group (n = 196) received 12 months of self-management support from nonphysician care coordinators, decision support electronic health records facilitating physician treatment adjustments, and specialist case reviews; they were followed up for an additional 12 months without intervention. Patients in the control group (n = 208) received usual care over 24 months. MAIN OUTCOMES AND MEASURES: The primary outcome was the between-group difference in the percentage of patients at 24 months who had at least a 50% reduction in Symptom Checklist Depression Scale (SCL-20) scores (range, 0-4; higher scores indicate worse symptoms) and a reduction of at least 0.5 percentage points in HbA1c, 5 mm Hg in SBP, or 10 mg/dL in LDL cholesterol. Prespecified secondary outcomes were percentage of patients at 12 and 24 months who met treatment targets (HbA1c <7.0%, SBP <130 mm Hg, LDL cholesterol <100 mg/dL [<70 mg/dL if prior cardiovascular disease]) or had improvements in individual outcomes (≥50% reduction in SCL-20 score, ≥0.5-percentage point reduction in HbA1c, ≥5-mm Hg reduction in SBP, ≥10-mg/dL reduction in LDL cholesterol); percentage of patients who met all HbA1c, SBP, and LDL cholesterol targets; and mean reductions in SCL-20 score, Patient Health Questionnaire-9 score, HbA1c, SBP, and LDL cholesterol. RESULTS: Among 404 patients randomized (mean [SD] age, 53 [8.6] years; 165 [40.8%] men), 378 (93.5%) completed the trial. A significantly greater percentage of patients in the intervention group vs the usual care group met the primary outcome (71.6% vs 57.4%; risk difference, 16.9% [95% CI, 8.5%-25.2%]). Of 16 prespecified secondary outcomes, there were no statistically significant between-group differences in improvements in 10 outcomes at 12 months and in 13 outcomes at 24 months. Serious adverse events in the intervention and usual care groups included cardiovascular events or hospitalizations (4 [2.0%] vs 7 [3.4%]), stroke (0 vs 3 [1.4%]), death (2 [1.0%] vs 7 [3.4%]), and severe hypoglycemia (8 [4.1%] vs 0). CONCLUSIONS AND RELEVANCE: Among patients with diabetes and depression in India, a 12-month collaborative care intervention, compared with usual care, resulted in statistically significant improvements in a composite measure of depressive symptoms and cardiometabolic indices at 24 months. Further research is needed to understand the generalizability of the findings to other low- and middle-income health care settings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02022111.
引用
- Ali MK, Chwastiak L, Poongothai S, et al. Effect of a Collaborative Care Model on Depressive Symptoms and Glycated Hemoglobin, Blood Pressure, and Serum Cholesterol Among Patients With Depression and Diabetes in India: The INDEPENDENT Randomized Clinical Trial. JAMA. 2020. PMID: 32809002. doi:10.1001/jama.2020.11747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。